Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes: A Meta-analysis (original) (raw)

Numerous glucose-lowering drugs are used to treat type 2 diabetes. To estimate the relative efficacy and safety associated with glucose-lowering drugs including insulin. Cochrane Library Central Register of Controlled Trials, MEDLINE, and EMBASE databases through March 21, 2016. Randomized clinical trials of 24 weeks' or longer duration. Random-effects network meta-analysis. The primary outcome was cardiovascular mortality. Secondary outcomes included all-cause mortality, serious adverse events, myocardial infarction, stroke, hemoglobin A1c (HbA1C) level, treatment failure (rescue treatment or lack of efficacy), hypoglycemia, and body weight. A total of 301 clinical trials (1 417 367 patient-months) were included; 177 trials (56 598 patients) of drugs given as monotherapy; 109 trials (53 030 patients) of drugs added to metformin (dual therapy); and 29 trials (10 598 patients) of drugs added to metformin and sulfonylurea (triple therapy). There were no significant differences in ...